{"prompt": "['22', 'MC1488 WEE1', 'MCCC', 'Note: patients with any of the above may be allowed after discussion amongst the', 'investigators including the principal investigator', '3.29a', 'Any of the following because this study involves an investigational agent whose', 'genotoxic, mutagenic and teratogenic effects on the developing fetus and', 'newborn are unknown:', 'Pregnant women', 'Nursing women', 'Men or women of childbearing potential who are unwilling to employ', 'adequate contraception', '3.29b Subject has had prescription or non-prescription drugs or other products known', 'to be sensitive CYP3A4 substrates or CYP3A4 substrates with a narrow', 'therapeutic index, or to be moderate to strong inhibitors / inducers of CYP3A4', 'which cannot be discontinued two weeks prior (alternatively 5 half lives if T1/2', 'is known) prior to Day 1 of dosing and withheld throughout the study until 2', 'weeks after the last dose of study drug (Appendix VI).', 'NOTE: Co-administration of aprepitant or fosaprepitant during this study is', 'prohibited.', 'Note: Individiual drugs exerting CYP interactions as listed in tables in Appendix', 'VI may be continued on a case by case basis if felt essential for patient', 'managment, after discussions and discretion of the treating physician.', 'The preferred azole anti-fungal medication is Fluconazole (alternatively', 'Posaconazole) which can be given during treatment with AZD1775 at the', \"treating physician's discretion, however with dose reductions of AZD1775\", 'by', '25-75% (i.e. from AZD1775 200mg to 150 or 100mg).', '3.29c', 'Pateints may not be on an inhibitor of BCRP as outlined in Appendix VI.', 'NOTE: AZD1775 is an inhibitor of breast cancer resistance protein (BCRP). The', 'use of statins including Atorvastatin which are substrates for BCRP are therefore', 'prohibited and patients should be moved on to non-BCRP alternatives.', '3.29d Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville', 'oranges, pummelos, and exotic citrus fruits from 7 days prior to the dose of study', 'medication and during the entire study due to potential CYP3A4 interaction with', 'the study medication. NOTE: Orange juice is allowed.', '3.29e Corrected QT interval (QTc) >470 msec (as calculated per institutional', 'standards) at study entry or congenital long QT syndrome.']['23', 'MC1488', '4.0', 'Test Schedule', 'Table 4.1: Test Schedule for Elderly Newly Diagnosed and Relapsed/Refractory AML patients', 'Active Monitoring Phase', '<14 days', '7 days', 'Cycle 1', 'Cycles 2 & 3 Days', 'Cycles 4+Day 1', 'EOS\u00b2', 'prior to', 'prior to', 'Days 1,', '1, 15, and 28 (+ 3', 'and Beyond(+/-3', 'Tests and procedures', 'registration', 'registration', '8, 15, &', 'days) 5,13', 'days) 5, 17', '28(+3', 'days5, 13', 'History and exam, wt, PS,', 'X', 'X', 'X13', 'X13', 'X', 'vitals', 'Height', 'X', 'Adverse event assessment', 'X', 'X', 'X', 'X', 'X', 'Hematology group', 'WBC', 'ANC', 'X', 'X', 'X', \"X'\", 'X', 'Hgb', 'PLT', 'Chemistry group: sodium,', 'potassium, calcium,', 'creatinine,', 'bicarbonate, glucose,', 'chloride, albumin,', 'X', 'X', 'X', 'X', 'X', 'BUN, alkaline', 'phosphatase, AST,', 'ALT, total protein,', 'total bilirubin, LDH', 'TLS monitoring (for', 'selected AML', 'patients): BUN,', 'calcium, CO2,', 'X14', 'X14', 'chloride, creatinine,', 'glucose, potassium,', 'sodium, uric acid,', 'phosphorus']\n\n###\n\n", "completion": "END"}